Basiliximab induction improves the outcome of renal transplants in children and adolescents

Pediatric Nephrology

Volumn 16, Issue 9, 2001, Pages 693-696

  Swiatecka Urban, A ^a   Garcia, C ^a   Feuerstein, D ^a   Suzuki, S ^a   Devarajan, P ^a   Schechner, R ^a   Greenstein, S ^a   Tellis, V ^a   Kaskel, F ^a  

^a Ira Greifer Pediatric Kidney Center   (United States)

Author keywords

Basiliximab; Post transplant diabetes mellitus; Post transplant lymphoproliferative disease; Tacrolimus; Target levels

Indexed keywords

COTRIMOXAZOLE; DAPSONE; GANCICLOVIR; INSULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; NYSTATIN; PREDNISONE; STEROID; TACROLIMUS;

ADOLESCENT; ADVERSE DRUG REACTION; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA MATCHING; HOSPITAL; HUMAN; KIDNEY GRAFT; LYMPHOPROLIFERATIVE DISEASE; MALE; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECIPIENT; SURVIVAL RATE; TIME; UNITED STATES;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE;

EID: 0034874885     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670100642     Document Type: Article

References (17)

1. Pediatric renal transplantation under tacrolimus-based immunosuppression
2. Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation
3. Randomised trial of basiliximab versus placebo for control of acute rejection in renal allograft recipients
4. Reduction in the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody
5. Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors
6. Experience with basiliximab in pediatric renal transplant recipients
7. Basiliximab (Simulect) dramatically reduces acute rejection after pediatric kidney transplantation
8. Basiliximab as induction therapy in pediatric renal transplantation: Single center experience from Essex, Germany
9. Clinical use of tacrolimus (FK 506) in infants and children with renal transplants
10. Tacrolimus in pediatric renal transplantation
11. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents
12. Pediatric renal transplantation under FK 506 immunosuppression
13. The side effects of FK 506 in humans
14. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression
15. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK 506)
16. Pharmacokinetics of FK 506 in transplant patients